Humira fuels AbbVie sales and earnings
Global sales for Illinois-based drug firm AbbVie rose 5 percent in the second quarter, driven primarily by a 26-percent jump in sales for its arthritis drug Humira.
AbbVie, which has research-and-development operations in Worcester, announced Friday that worldwide sales for the quarter were $4.926 billion. Meanwhile, the company reported net earnings of $1.09 billion, or 68 cents a share, compared with $1.06 billion, or 66 cents for the second quarter of 2013.
The company recently announced it would buy Dublin-based pharmaceuticals company Shire for $54 billion. AbbVie intends to move its global headquarters to the United Kingdom while keeping its operational headquarters in Chicago.
"This was another very strong quarter for AbbVie, as we delivered sales and earnings per share above our original guidance and announced plans to merge with Shire, a strategic action that will further enhance our long-term growth prospects," said Richard A. Gonzalez, chairman and chief executive officer, in a statement. “We continue to expect positive trends for the second half of the year, as well as additional progress from our pipeline, including the expected U.S. approval of our interferon-free HCV combination."
WBJ Web Partners
Most Recent
Most Recent
0 Comments